Skip to content

Ketogenic diet therapy for rare epilepsy syndromes, multicenter randomly controlled clinical trial

Ketogenic diet therapy for rare epilepsy syndromes, multicenter randomly controlled clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-16008342
Enrollment
Unknown
Registered
2016-04-22
Start date
2016-05-31
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rare epilepsy syndromes

Interventions

treatment :ketogenic diet
control:antiepileptic drugs

Sponsors

Shenzhen Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Intractable epilepsy, or ASD with or without epilepsy; Conform to the study of disease diagnosis standard, part of disease should be genetic diagnosis. Major diseases are: 1.Landau-Kleffner syndromeAngelman syndrome; 2.Dravet syndromeRett syndrome; 3.Doose syndrome; 4.ASD(autism spectrum disorders), with or without epilepsy; 5.Cortical dysplasia with intractable epilepsy; 6.Autoimmune encephalitis combined intractable epilepsy; 7.Infantile spasms; 8.Tuberous sclerosis with epilepsy; 9.Intractable epilepsy and tic disorder or ADHD combility; 10.Refractory epilepsy combined low intelligence; 11.Refractory epilepsy combined speech retarded; 12.Mitochondrial diseases such as metabolic disease; 13.Lennox-Gastaut syndrome, epilepsy surgery failure cases of ketogenic diet therapy (adult); 14.Super refractory status epilepticus; 15.Pachygyria malformation combined intractable epilepsy; 16.Pyruvate dehydrogenase deficiency, cohort; 17.Glut-1 deficiency syndrome, cohort.

Exclusion criteria

Exclusion criteria: Diagnosis is not completely in line with cases; There are genetic metabolic diseases that contraindicated by ketogenic diet therapy; Patients with severe diseases in major organs; The guardian can't cooperate, or can't understand the research.

Design outcomes

Primary

MeasureTime frame
Percentage of seizure reduction;response rate;with or without epileptic spasms;behavioral and devlopment;

Countries

China

Contacts

Public ContactQin Jiong, Liao Jianxiang

Peking University People's Hospital

qinjiong@gmail.com+86 010 88326666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026